ERBB2 and triple-negative breast carcinoma: Furthermore, for patients who are not candidates for endocrine and/or anti-HER2 therapy, the exploration of innovative strategies, such as the use of immunotherapy concomitant with neoadjuvant chemotherapy in patients with triple-negative breast cancer, may be a potential pathway for improving these outcomes38.